At the core of this framework is the critical role glycolysis plays in rapid ATP generation necessary for essential cellular processes. Glycolysis serves as the primary source of quick energy fueling cell proliferation, DNA synthesis, and mitochondrial maintenance. Taguchi and colleagues argue that an age-dependent decrease in glycolytic ATP supply progressively weakens these vital repair and regeneration mechanisms, fundamentally shaping the phenotypes of aging observed throughout the animal kingdom.

This theory diverges significantly from classical aging hypotheses that focus predominantly on oxidative damage accumulation or telomere shortening. Instead, it posits that the metabolic shift away from glycolysis towards oxidative phosphorylation, while more energy-efficient, compromises the quick ATP availability required for immediate cellular repair. The consequent decline in repair capability leads to the accumulation of molecular and organellar damage that typifies aging tissues.

The researchers substantiate their argument with comparative biology evidence, contrasting short-lived rodents with long-lived species like the naked mole rat. Notably, naked mole rats sustain high glycolytic flux even in low-oxygen microenvironments, enabling continuous ATP production and exceptional longevity. Such observations suggest that species have evolved distinct metabolic strategies to balance energy efficiency and repair capacity optimally over their lifespans.

Furthermore, the perspective elucidates molecular pathways linking glycolytic ATP production to cellular quality control processes such as mitophagy, telomere dynamics, and proteostasis. Sustaining high glycolytic flux supports these pathways, ensuring maintenance of genomic integrity and proteome stability, thereby delaying age-associated functional decline. Conversely, an enforced metabolic transition to oxidative phosphorylation reduces glycolytic contributions, undermining these protective networks and hastening aging.

The authors also consider the evolutionary rationale, proposing that natural selection favored species with an optimal rate of glycolytic ATP decline. Species exhibiting either too rapid or too slow a reduction in glycolytic capacity would likely suffer fitness disadvantages, underscoring aging as an evolved, regulated process rather than mere wear-and-tear. This contention reframes aging as a metabolically programmed trajectory sculpted by energy allocation priorities across generations.

To rigorously test this provocative hypothesis, Taguchi’s team delineates several experimental avenues. These include genetic and pharmacologic interventions to modulate glycolytic enzyme activity in vivo and in vitro. For instance, gene transfer approaches targeting key glycolytic enzymes or application of drugs like terazosin, known to stimulate glycolysis, could ascertain if enhancing glycolytic ATP production rejuvenates repair systems and extends cellular and organismal longevity.

Additionally, longitudinal studies measuring glycolytic ATP output across age cohorts in diverse species with varying lifespans will be critical to delineate the “optimal rate” of glycolytic decline. Complementary comparative analyses could identify metabolic signatures linked to longevity, enabling predictive models of aging based on metabolic profiling. These efforts aim to connect molecular metabolism with evolutionary biology and lifespan determination.

A particularly novel aspect under investigation is metabolic coupling via gap junctions between hematopoietic stem cells and endothelial cells, a potential mechanism for distributing glycolytic ATP to critical regenerative niches. Deciphering such intercellular energy-sharing networks could uncover new targets for therapeutic intervention to mitigate age-related degeneration across tissue systems.

Despite the compelling coherence of the model, the authors emphasize its current status as a hypothesis requiring empirical validation. They caution that translation into human therapies—whether stem cell-based, metabolic activators, or gene therapies—demands meticulous preclinical evaluation of safety, efficacy, and long-term outcomes. Moreover, the evolutionary basis warrants deeper mechanistic and comparative research to substantiate the concept of a selected, programmed glycolytic decline.

This paradigm-shifting perspective invites a fundamental reconsideration of aging biology, highlighting the pivotal influence of glycolytic metabolism in lifespan regulation. It postulates that rather than oxidative damage alone, an orchestrated modulation of glycolytic ATP generation orchestrates the balance between energy efficiency, rapid repair capacity, and longevity. If borne out, such insights could revolutionize strategies aimed at extending healthspan and counteracting age-related diseases.

By uniting metabolic biochemistry, evolutionary theory, and aging physiology, this work sets the stage for a new era in aging research. It challenges researchers to explore glycolytic flux not just as a metabolic parameter, but as a central determinant of biological aging trajectories shaped by natural selection. Unlocking the molecular levers of glycolytic control could soon provide revolutionary avenues to delay aging and promote regenerative health in humans.

As this hypothesis undergoes further experimental scrutiny, it promises to inspire transformative innovations in anti-aging science, catalyzing developments from bench to bedside. Future studies dissecting glycolytic regulation within specific stem cell populations and tissue microenvironments will be critical to delineate mechanistic underpinnings and therapeutic potential. The tantalizing prospect of metabolically reprogramming aging processes may herald a new frontier in gerontology and regenerative medicine.

The research spearheaded by Taguchi and collaborators opens fresh intellectual vistas linking metabolic flux with lifespan modulation, presenting a refined, integrative narrative of aging biology. As the field embraces this interplay between energy metabolism and aging phenotypes, novel biomarkers and interventions targeting glycolytic pathways are poised to emerge. Ultimately, this framework could redefine our approach to prolonging longevity and enhancing resilience against age-associated decline.

Subject of Research:
Not applicable

Article Title:
A decline in glycolytic ATP production is the fundamental mechanism limiting lifespan; species with an optimal rate of decline over time survived

News Publication Date:
24-Feb-2026

Web References:
https://doi.org/10.18632/aging.206356
https://www.aging-us.com/issue/v18i1/

Image Credits:
Copyright: © 2026 Taguchi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).

Keywords:
hypothesis, aging, glycolytic ATP production, lifespan, Heterocephalus glaber

This year’s cohort of awardees embodies a diverse range of scientific inquiries, exemplifying the multifaceted approach required to decipher the complex biological and molecular processes underlying aging. Their investigations extend from cellular metabolism and immune regulation to neurobiology and regenerative medicine, reflecting AFAR’s commitment to supporting high-impact research across the full spectrum of aging biology.

One highlighted recipient, Dr. Jacob Brown from Florida State University, is exploring the therapeutic potential of oxylipins in ameliorating muscle atrophy induced by disuse during aging. Oxylipins are lipid-derived signaling molecules implicated in inflammation and tissue repair. Dr. Brown’s work seeks to determine whether modulating these pathways might enhance recovery from muscle deterioration, a significant contributor to frailty in elderly populations. This could pave the way for novel interventions targeting muscle resilience in aging individuals.

At Harvard Medical School, Dr. Ang Cui is delving into the intricacies of cytokine signaling and its influence on hematopoietic stem cell (HSC) fate decisions with age. Hematopoietic stem cells are responsible for maintaining blood cell populations, but their function declines as we age, contributing to immunosenescence and heightened disease susceptibility. Dr. Cui’s project aims to decode how cytokine milieus direct HSC differentiation and renewal, potentially uncovering molecular targets to rejuvenate aged immune systems.

Another promising investigation by Dr. Madison Doolittle at the University of Connecticut Health Center focuses on the phenomenon of premature aging and persistent cellular senescence following tissue injury resolution. Senescent cells—cells that cease dividing but remain metabolically active—accumulate with age and contribute to chronic inflammation and tissue dysfunction. Dr. Doolittle’s research attempts to discern how these residual senescent cells after injury might accelerate aging processes, providing insights crucial for developing senolytic therapies that selectively clear harmful senescent cells.

Neuroimmunology is represented by Dr. Sija He from the University of Texas Health San Antonio, who is investigating brain innate immunity’s role in regulating systemic aging. The central nervous system’s immune environment profoundly influences peripheral organ function and systemic homeostasis. Dr. He’s research may elucidate mechanisms by which neuroimmune interactions impact aging trajectories, potentially informing novel interventions for age-associated neurological and systemic disorders.

At the University of California Riverside, Dr. Huimin Zhang is advancing knowledge on T cell aging, specifically looking at the epigenetic regulation mediated by the transcription factor HELIOS and its impact on follicular helper T (TFH) cell differentiation. TFH cells are critical for adaptive immunity and vaccine responses, which wane with age. Understanding HELIOS’s role could reveal epigenetic manipulation strategies to bolster immune competence in older adults.

Dr. Meng Zhang at Scripps Research is pioneering the use of spatial multi-omics—the combined analysis of spatially resolved transcriptomics, proteomics, and metabolomics—to unravel neuro-immune crosstalk. His work captures the dynamic molecular dialogues within aging tissues, aiming to identify key signaling networks that drive age-related functional decline. This integrative approach promises a comprehensive mapping of aging biology at unprecedented resolution.

AFAR’s Grants for Junior Faculty are not only a source of financial backing but also a recognition of scientific promise at a turning point in researchers’ careers. Stephanie Lederman, EdM, Executive Director of AFAR, emphasizes that this grant program is “a core grant program since AFAR’s inception,” signifying its foundational role in nurturing talent that has continually pushed the frontier of aging research. These grants serve as essential catalysts enabling scientists to generate preliminary data, publish influential findings, and secure future funding.

The support system behind these grants is robust, with backing from philanthropic foundations such as the Marion Esser Kaufmann Foundation and the Hearst Foundations providing targeted underwriting. Additionally, the AFAR Board of Directors, along with numerous anonymous donors and charitable trusts, contribute to a diversified funding portfolio ensuring program sustainability. This collaborative funding ecosystem enables a high level of competitive support that sustains scientific innovation.

For over four decades, AFAR has been at the forefront of biomedical aging research, distributing over $225 million to more than 4,500 investigators across premier institutions. The organization’s strategic role transcends grantmaking; AFAR also coordinates interdisciplinary research networks and public-private partnerships, fostering a collaborative environment that accelerates translational breakthroughs. In 2025 alone, AFAR anticipates allocating over $12 million in funding to nearly 80 investigators, reflecting sustained commitment to combating age-related diseases and improving healthspan.

The scientific insights emerging from AFAR-supported projects increasingly reveal the plasticity of aging processes at the cellular and molecular levels. By modifying fundamental pathways such as inflammation, epigenetic regulation, and stem cell function, researchers are demonstrating that aging is not a fixed destiny but a malleable biological state. This paradigm shift lays the groundwork for therapies that could delay multiple chronic diseases simultaneously, extending both lifespan and quality of life.

AFAR’s portfolio is driving a new era in aging research, where innovative methodologies like spatial multi-omics, advanced immunophenotyping, and targeted epigenetic interventions converge. The junior faculty currently funded through this program embody the next generation of thought leaders poised to revolutionize geroscience. Their work holds the promise of transforming clinical paradigms by enabling early interventions that preserve tissue function, enhance immune resilience, and mitigate degenerative processes.

Ultimately, these grants represent more than financial support; they symbolize a strategic investment in the future of aging science. By empowering early-career scientists to pursue high-risk, high-reward studies, AFAR is catalyzing knowledge that will unlock therapeutic potentials and shape public health trajectories. As our global population ages, this pioneering research is vital to ensuring that longer lives are paired with sustained health and vitality.

For further information about the Grants for Junior Faculty and other research support opportunities, interested parties can visit AFAR’s official website, where detailed program descriptions and application guidelines are available. This transparent and accessible approach fosters broader engagement with the aging research community, encouraging collaborative innovation to tackle one of the most pressing biomedical challenges of our time.

—

Subject of Research: Biology of Aging and Age-Related Mechanisms
Article Title: Emerging Breakthroughs in Aging Biology: AFAR’s 2025 Junior Faculty Grants Propel Next-Generation Research
News Publication Date: 2025
Web References: https://www.afar.org/grants/afar-research-grants-1-2
References: Information sourced from AFAR official grant announcements and investigator profiles
Image Credits: AFAR Publications
Keywords: Aging, Biology of Aging, Geroscience, Oxylipins, Hematopoietic Stem Cells, Cellular Senescence, Neuroimmunity, Epigenetic Regulation, Spatial Multi-omics, Junior Faculty Grants

The allure of NAD⁺ precursors as anti-ageing interventions originates from their capacity to replenish cellular NAD⁺ pools, thereby ostensibly restoring metabolic balance and enhancing cellular repair mechanisms. In rodent models, supplementation with compounds such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) has been associated with improvements in mitochondrial function, cognitive performance, and lifespan extension. However, human clinical trials investigating the efficacy of NAD⁺ precursor supplements have largely produced modest or equivocal outcomes. These discrepancies underscore the complexity of NAD⁺ metabolism in humans and hint at nuanced, tissue-specific dynamics that diverge from those observed in animal models.

Critically, the quantification of NAD⁺ levels in human tissues remains a formidable challenge, constrained by the invasiveness of sampling techniques and the paucity of longitudinal data. Unlike rodents, where tissue biopsies can be systematically obtained and analyzed, human studies often rely on peripheral blood or limited tissue biopsies, which may not fully capture the systemic and local variations of NAD⁺ status. Moreover, the heterogeneity of human populations, influenced by genetics, lifestyle, diet, and comorbidities, adds layers of variability challenging the interpretation of NAD⁺ dynamics with ageing.

Emerging evidence tentatively confirms an age-associated decline in NAD⁺ in select human tissues such as skeletal muscle and brain, yet this decline is neither universal nor consistent across all studies. The complexity deepens when considering NAD⁺ precursor supplementation, which has shown variable efficacy across different tissues. For instance, some studies report increased NAD⁺ concentrations in skeletal muscle or blood following NR or NMN administration, while others detect minimal or transient changes. This variability raises pivotal questions about the bioavailability, tissue targeting, and metabolic fate of supplemented precursors in humans.

At the molecular level, NAD⁺ functions both as a substrate for enzymes like sirtuins and poly(ADP-ribose) polymerases (PARPs) and as a redox carrier shuttling electrons during metabolic reactions. The balance between NAD⁺ synthesis, consumption, and recycling governs cellular energetic and stress responses. Ageing disrupts this balance by elevating NAD⁺ consumption through DNA damage and chronic inflammation, simultaneously impairing biosynthetic pathways. Understanding how these opposing forces influence NAD⁺ pools in distinct tissues remains fundamental for devising effective therapeutic strategies.

In addition to systemic factors, intracellular compartmentalization of NAD⁺ adds complexity. NAD⁺ pools exist in cytosolic, nuclear, and mitochondrial compartments, each fulfilling unique roles. The crosstalk between these pools and their regulation may vary with age and disease states, potentially explaining the differential responses observed upon supplementation. Current analytical methods often measure total NAD⁺ without resolving compartment-specific dynamics, limiting mechanistic insights.

Clinical trials to date have predominantly focused on relatively healthy older adults, often employing short-duration supplementation and limited dosing regimens. Such parameters may be insufficient to elicit measurable biological effects, especially considering age-related declines in NAD⁺ biosynthetic efficiency and possible alterations in precursor uptake or metabolism. Future studies will need to explore optimized dosing, duration, and combination therapies, as well as stratify participants based on metabolic and molecular biomarkers to identify responders versus non-responders.

Beyond ageing, NAD⁺ metabolism intersects intimately with various pathological conditions, including metabolic syndrome, neurodegenerative diseases, and cardiovascular disorders. The interplay between disease processes and NAD⁺ homeostasis may complicate interpretation of supplementation outcomes. For example, chronic diseases may impose heightened NAD⁺ consumption or impair salvage pathways, necessitating tailored therapeutic approaches. Personalized medicine frameworks incorporating NAD⁺ metabolism profiling could enhance intervention efficacy.

Furthermore, the safety profile of long-term NAD⁺ precursor supplementation warrants thorough investigation. While generally well-tolerated in short-term trials, potential off-target effects, metabolic imbalances, or perturbations of cellular signaling pathways must be carefully scrutinized in larger and extended studies. Regulatory oversight and standardized protocols will be crucial as these compounds gain popularity as nutraceuticals.

Technological advancements in mass spectrometry, imaging, and omics methodologies promise to shed light on the intricate landscape of NAD⁺ metabolism across tissues and disease states. These tools enable quantification of NAD⁺ and related metabolites with high spatial and temporal resolution, providing unprecedented opportunities to elucidate mechanisms underlying NAD⁺ dynamics and to refine supplementation strategies.

In sum, the enthusiasm for NAD⁺ precursor supplementation as a panacea for ageing-related decline is tempered by a nascent and fragmented clinical evidence base. Bridging the translational gap from rodent models to humans demands a concerted effort to conduct comprehensive, multisystem clinical studies integrating molecular, cellular, and physiological endpoints. Such endeavors will clarify the true potential and limitations of NAD⁺-targeted therapies in promoting healthy human ageing.

Ultimately, advancing this field hinges on embracing the biological complexity of NAD⁺ metabolism and recognizing the multifactorial nature of ageing. Integrative research initiatives that factor in genetics, lifestyle, metabolic health, and environmental exposures are essential to devise precision interventions. As the scientific community accelerates towards these goals, NAD⁺ precursor supplementation remains a compelling yet evolving frontier in the quest to decipher and modulate the ageing process.

Subject of Research:
Nicotinamide adenine dinucleotide (NAD⁺) metabolism and its modulation through precursor supplementation in the context of human ageing.

Article Title:
NAD⁺ precursor supplementation in human ageing: clinical evidence and challenges.

Article References:
Vinten, K.T., Trętowicz, M.M., Coskun, E. et al. NAD⁺ precursor supplementation in human ageing: clinical evidence and challenges. Nat Metab (2025). https://doi.org/10.1038/s42255-025-01387-7

Image Credits: AI Generated